000 01234cam a2200313 i 4500
008 151106s2019 flua b 001 0 eng
020 _a9781498750394 (hardcover : acid-free paper)
_cRM616.66
040 _aUKM
_erada
090 _aQV241
_b.N577b 2019 9
100 1 _aNiazi, Sarfaraz,
_d1949-
_eauthor.
245 1 0 _aBiosimilarity :
_bthe FDA perspective /
_cSarfarz K. Niazi.
264 1 _aBoca Raton :
_bCRC Press, Taylor & Francis Group,
_c[2019]
300 _axxxvii, 397 pages :
_bcolor illustrations ;
_c27 cm
336 _atext
_2rdacontent
337 _aunmediated
_2rdamedia
338 _avolume
_2rdacarrier
504 _aIncludes bibliographical references and index.
650 1 2 _aBiosimilar Pharmaceuticals
_zUnited States.
650 2 2 _aDrug Approval
_zUnited States.
650 2 2 _aGovernment Regulation
_zUnited States.
650 2 2 _aUnited States Government Agencies
_zUnited States.
907 _a.b16789842
_b2020-03-10
_c2020-01-22
942 _c01
_n0
_kQV241 .N577b 2019 9
949 _o900156777
990 _alm
991 _aFakulti Farmasi, PDAL
998 _ad0001
_b2020-01-22
_cm
_da
_feng
_gflu
_y0
_z.b16789842
999 _c646462
_d646462